Clinical Trial Update: Persistence of Immune Response After Vaccination With MCC [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating durability of the immune response after MCC vaccination for prevention of meningococcal infection; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MCC (Meningococcal conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Prevention of Meningococcal Infection | Phase 4 | Status: COMPLETED